Use of [18F]FDOPA-PET for in vivo evaluation of dopaminergic dysfunction in unilaterally 6-OHDA-lesioned rats

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-12

  Kyono, Kiyoshi ^a,b   Takashima, Tadayuki ^b   Katayama, Yumiko ^b   Kawasaki, Toshiyuki ^b   Zochi, Riyo ^b   Gouda, Maki ^a   Kuwahara, Yasuhiro ^a   Takahashi, Kazuhiro ^b   Wada, Yasuhiro ^b   Onoe, Hirotaka ^b   Watanabe, Yasuyoshi ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b RIKEN   (Japan)

Author keywords

6 OHDA; Dopamine; Parkinson's disease; Positron emission tomography

Indexed keywords

6 FLUORODOPA F 18; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; METABOLITE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIOCHROMATOGRAPHY; RAT;

EID: 84875912332     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-25     Document Type: Article

References (60)

1. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I: Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009, 8:1150-1157.
2. Obeso JA, Olanow CW, Nutt JG: Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000, 23:S2-7.
3. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O: Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002, 99:2344-2349.
4. Ben-Hur T, Idelson M, Khaner H, Pera M, Reinhartz E, Itzik A, Reubinoff BE: Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 2004, 22:1246-1255.
5. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y, Hashimoto N: Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 2005, 115:102-109.
6. Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M, Mizukami H, Urabe M, Kume A, Nagatsu I, Urano F, Suzuki T, Ichinose H, Nagatsu T, Monahan J, Nakano I, Ozawa K: Triple transduction with adenoassociated virus vectors expressing tyrosine hydroxylase, aromatic-lamino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000, 11:1509-1519.
7. Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terao K, Nakano I, Ozawa K: Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopaminesynthesizing enzymes. Hum Gene Ther 2002, 13:345-354.
8. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ: Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000, 20:4686-4700.
9. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D: Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 2005, 25:769-777.
10. Ungerstedt U: Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl 1971, 367:49-68.
11. Deumens R, Blokland A, Prickaerts J: Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002, 175:303-317.
12. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS: Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990, 28:547-555.
13. Garnett ES, Firnau G, Nahmias C, Carbotte R, Bartolucci G: Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease. J Neurol Sci 1984, 65:231-237.
14. Nahmias C, Garnett ES, Firnau G, Lang A: Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985, 69:223-230.
15. Holthoff-Detto VA, Kessler J, Herholz K, Bonner H, Pietrzyk U, Wurker M, Ghaemi M, Wienhard K, Wagner R, Heiss WD: Functional effects of striatal dysfunction in Parkinson disease. Arch Neurol 1997, 54:145-150.
16. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS: The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990, 47:1290-1298.
17. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O: Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 2000, 57:470-475.
18. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ: Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997, 41:58-64.
19. Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, Mandel F, Spetsieris P, Eidelberg D: Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994, 35:955-963.
20. Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O: Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999, 67:737-741.
21. Strome EM, Cepeda IL, Sossi V, Doudet DJ: Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol Imaging Biol 2006, 8:292-299.
22. Sossi V, Holden JE, Topping GJ, Camborde ML, Kornelsen RA, McCormick SE, Greene J, Studenov AR, Ruth TJ, Doudet DJ: In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood Flow Metab 2007, 27:1407-1415.
23. Collantes M, Penuelas I, Alvarez-Erviti L, Blesa J, Marti-Climent JM, Quincoces G, Delgado M, Ecay M, Martinez A, Arbizu J, Rodriguez-Oroz MC, Obeso J, Richter JA: [Use of 11C-(+)-alpha-dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease]. Rev Esp Med Nucl 2008, 27:103-111.
24. Sossi V, Dinelle K, Topping GJ, Holden JE, Doudet D, Schulzer M, Ruth TJ, Stoessl AJ, de la Fuente-Fernandez R: Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem 2009, 109:85-92.
25. Topping GJ, Dinelle K, Kornelsen R, McCormick S, Holden JE, Sossi V: Positron emission tomography kinetic modeling algorithms for small animal dopaminergic system imaging. Synapse 2010, 64:200-208.
26. Wang JL, Oya S, Parhi AK, Lieberman BP, Ploessl K, Hou C, Kung HF: In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease. Nucl Med Biol 2010, 37:479-486.
27. Hume SP, Lammertsma AA, Myers R, Rajeswaran S, Bloomfield PM, Ashworth S, Fricker RA, Torres EM, Watson I, Jones T: The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J Neurosci Methods 1996, 67:103-112.
28. Inaji M, Okauchi T, Ando K, Maeda J, Nagai Y, Yoshizaki T, Okano H, Nariai T, Ohno K, Obayashi S, Higuchi M, Suhara T: Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 2005, 1064:136-145.
29. Inaji M, Yoshizaki T, Okauchi T, Maeda J, Nagai Y, Nariai T, Ohno K, Ando K, Okano H, Obayashi S, Suhara T: In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDAlesioned rats. Cell Transplant 2005, 14:655-663.
30. Pellegrino D, Cicchetti F, Wang X, Zhu A, Yu M, Saint-Pierre M, Brownell AL: Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. J Nucl Med 2007, 48:1147-1153.
31. Rodriguez-Gomez JA, Lu JQ, Velasco I, Rivera S, Zoghbi SS, Liow JS, Musachio JL, Chin FT, Toyama H, Seidel J, Green MV, Thanos PK, Ichise M, Pike VW, Innis RB, McKay RD: Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells 2007, 25:918-928.
32. Casteels C, Lauwers E, Bormans G, Baekelandt V, Van Laere K: Metabolicdopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease. Eur J Nucl Med Mol Imaging 2008, 35:124-134.
33. Forsback S, Niemi R, Marjamaki P, Eskola O, Bergman J, Gronroos T, Haaparanta M, Haapalinna A, Rinne J, Solin O: Uptake of 6-[18F]fluoro-ldopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease. Synapse 2004, 51:119-127.
34. Ito Y, Fujita M, Shimada S, Watanabe Y, Okada T, Kusuoka H, Tohyama M, Nishimura T: Comparison between the decrease of dopamine transporter and that of l-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse 1999, 31:178-185.
35. Poyot T, Conde F, Gregoire MC, Frouin V, Coulon C, Fuseau C, Hinnen F, Dolle F, Hantraye P, Bottlaender M: Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-l-dopa. J Cereb Blood Flow Metab 2001, 21:782-792.
36. Ishida Y, Kawai K, Magata Y, Abe H, Yoshimoto M, Takeda R, Hashiguchi H, Mukai T, Saji H: Alteration of striatal [11C]raclopride and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats. Neurosci Lett 2005, 389:30-34.
37. Ishiwata K, Shinoda M, Ishii S, Nozaki T, Senda M: Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism. Nucl Med Biol 1996, 23:295-301.
38. Paxinos G, Watson C: The rat brain in stereotaxic coordinates. 6 edition. Amsterdam; Boston;: Academic Press/Elsevier; 2007.
39. Patlak CS, Blasberg RG, Fenstermacher JD: Graphical evaluation of bloodto-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983, 3:1-7.
40. Melega WP, Luxen A, Perlmutter MM, Nissenson CH, Phelps ME, Barrio JR: Comparative in vivo metabolism of 6-[18F]fluoro-l-dopa and [3H]l-dopa in rats. Biochem Pharmacol 1990, 39:1853-1860.
41. Matsumura A, Mizokawa S, Tanaka M, Wada Y, Nozaki S, Nakamura F, Shiomi S, Ochi H, Watanabe Y: Assessment of microPET performance in analyzing the rat brain under different types of anesthesia: comparison between quantitative data obtained with microPET and ex vivo autoradiography. Neuroimage 2003, 20:2040-2050.
42. Pauwels T, Dethy S, Goldman S, Monclus M, Luxen A: Effect of catechol-Omethyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-l-dopa. Eur J Pharmacol 1994, 257:53-58.
43. Brust P, Vorwieger G, Walter B, Fuchtner F, Stark H, Kuwabara H, Herzau M, Opfermann T, Steinbach J, Ganapathy V, Bauer R: The influx of neutral amino acids into the porcine brain during development: a positron emission tomography study. Brain Res Dev Brain Res 2004, 152:241-253.
44. del Amo EM, Urtti A, Yliperttula M: Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 2008, 35:161-174.
45. Choi TB, Pardridge WM: Phenylalanine transport at the human bloodbrain barrier. Studies with isolated human brain capillaries. J Biol Chem 1986, 261:6536-6541.
46. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I: Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-DOPA in the rat, with reference to the involvement of aromatic l-amino acid decarboxylase. Brain Res 1994, 667:295-299.
47. Arai R, Karasawa N, Nagatsu I: Aromatic l-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A doublelabeling immunofluorescence study. Brain Res 1996, 706:177-179.
48. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M: Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
49. Lopez A, Munoz A, Guerra MJ, Labandeira-Garcia JL: Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 2001, 103:639-651.
50. Navailles S, Bioulac B, Gross C, De Deurwaerdere P: Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 2010, 38:136-143.
51. Melamed E, Hefti F, Wurtman RJ: Decarboxylation of exogenous l-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries. Brain Res 1980, 198:244-248.
52. Melamed E, Hefti F, Liebman J, Schlosberg AJ, Wurtman RJ: Serotonergic neurones are not involved in action of l-dopa in Parkinson's disease. Nature 1980, 283:772-774.
53. Hefti F, Melamed E, Wurtman RJ: The decarboxylation of DOPA in the parkinsonian brain in vivo studies on an animal model. J Neural Transm Suppl 1980, 95-101.
54. Hefti F, Melamed E, Wurtman RJ: The site of dopamine formation in rat striatum after l-dopa administration. J Pharmacol Exp Ther 1981, 217:189-197.
55. Mura A, Jackson D, Manley MS, Young SJ, Groves PM: Aromatic l-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous l-DOPA to dopamine. Brain Res 1995, 704:51-60.
56. Tashiro Y, Kaneko T, Sugimoto T, Nagatsu I, Kikuchi H, Mizuno N: Striatal neurons with aromatic l-amino acid decarboxylase-like immunoreactivity in the rat. Neurosci Lett 1989, 100:29-34.
57. Hudson JL, van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA: Correlation of apomorphine-and amphetamineinduced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993, 626:167-174.
58. Lee CS, Sauer H, Bjorklund A: Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996, 72:641-653.
59. Sonntag KC, Pruszak J, Yoshizaki T, van Arensbergen J, Sanchez-Pernaute R, Isacson O: Enhanced yield of neuroepithelial precursors and midbrainlike dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 2007, 25:411-418.
60. Chiba S, Lee YM, Zhou W, Freed CR: Noggin enhances dopamine neuron production from human embryonic stem cells and improves behavioral outcome after transplantation into Parkinsonian rats. Stem Cells 2008, 26:2810-2820.